var data={"title":"Finasteride: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Finasteride: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6198?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=finasteride-patient-drug-information\" class=\"drug drug_patient\">see &quot;Finasteride: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47022773\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Finasteride Safety Review</span>\n      <span class=\"collapsible-date\">June 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada&rsquo;s review of the risk for potentially serious muscle-related adverse effects with the use of finasteride secondary to reports of these effects in patients treated with Propecia and Proscar has concluded this risk could not be eliminated. Health Canada is recommending manufacturers update finasteride-containing product information regarding this potential risk.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-finasteride-assessing-potential-risk-serious-muscle-related-side-effects.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171302\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Propecia;</li>\n      <li>Proscar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171303\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACH-Finasteride;</li>\n      <li>ACT-Finasteride;</li>\n      <li>Apo-Finasteride;</li>\n      <li>Auro-Finasteride;</li>\n      <li>Dom-Finasteride;</li>\n      <li>JAMP-Finasteride;</li>\n      <li>Mint-Finasteride;</li>\n      <li>Mylan-Finasteride;</li>\n      <li>Mylan-Finasteride HG;</li>\n      <li>PMS-Finasteride;</li>\n      <li>Propecia;</li>\n      <li>Proscar;</li>\n      <li>RAN-Finasteride;</li>\n      <li>ratio-Finasteride;</li>\n      <li>Sandoz-Finasteride;</li>\n      <li>Sandoz-Finasteride A;</li>\n      <li>Teva-Finasteride;</li>\n      <li>VAN-finasteride</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171346\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        5 Alpha-Reductase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171305\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Benign prostatic hyperplasia (Proscar):</b> Males: Oral: 5 mg once daily (either as a single agent or in combination with doxazosin); early responses may occur although 6 months of treatment is usually needed to assess benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Male pattern baldness (Propecia):</b> Males: Oral: 1 mg once daily; may take 3 months or longer of daily use for observed benefit; continued use is recommended to sustain benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Female hirsutism, idiopathic (off-label use):</b> Females: Oral: 5 mg once daily (Beigi, 2004; Lumachi, 2003; Moghetti, 2000) or 2.5 mg once daily (Tartagni 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Female hirsutism, related to polycystic ovary syndrome (off-label use):</b> Females: Oral: 5 mg once daily (Beigi 2004; Moghetti 2000) or 2.5 mg once daily (Tartagni 2004). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171306\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171307\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171308\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution (finasteride is metabolized extensively in the liver)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171276\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Propecia: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proscar: 5 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg, 5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171262\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171280\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with or without meals. Females of childbearing age should not touch or handle crushed or broken tablets.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104520\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171279\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Androgenetic alopecia (Propecia):</b> Treatment of male pattern hair loss in <b>men only</b>. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Limitations of use: Efficacy in bitemporal recession has not been established; not indicated for use in women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Benign prostatic hyperplasia (Proscar):</b> Treatment (monotherapy) of symptomatic benign prostatic hyperplasia (BPH) to improve symptoms, reduce the risk of acute urinary retention, and to reduce the risk of need for BPH-related surgery); used in combination with an alpha-blocker (doxazosin) to reduce the risk of symptomatic progression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Limitations of use: Not approved for the prevention of prostate cancer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725588\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Female hirsutism (idiopathic); Female hirsutism (related to polycystic ovary syndrome)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171352\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Finasteride may be confused with dutasteride, furosemide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proscar may be confused with ProSom, Provera, PROzac</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171269\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> &ldquo;Combination therapy&rdquo; refers to finasteride and doxazosin. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Orthostatic hypotension (combination therapy 18%; monotherapy 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (combination therapy 23%; monotherapy 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Decreased libido (combination therapy 12%; monotherapy 2% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Impotence (combination therapy 23%; monotherapy 5% to 19%), ejaculatory disorder (combination therapy 14%; monotherapy &lt;1% to 7%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (combination therapy 17%; monotherapy 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (combination therapy 3%; monotherapy 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Drowsiness (combination therapy 3%; monotherapy 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (monotherapy 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Gynecomastia (monotherapy 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Decreased ejaculate volume (monotherapy 2% to 4%), breast tenderness (monotherapy &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Dyspnea (combination therapy 2%; monotherapy 1%), rhinitis (combination therapy 2%; monotherapy 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Altered mental status, change in libido, decreased testicular size, depression, disturbed sleep, hypersensitivity (angioedema, facial swelling, pharyngeal edema, pruritus, skin rash, swelling of the lips, swollen tongue, urticaria), male infertility (temporary), malignant neoplasm of the male breast, prostate cancer - high grade, prostatitis, reduction in penile curvature, reduction in penile size, sexual disorder (may not be reversible with discontinuation), testicular pain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171283\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to finasteride or any component of the formulation; pregnancy or women of childbearing potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171266\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diminished urinary flow: Carefully monitor patients with a large residual urinary volume or severely diminished urinary flow for obstructive uropathy; these patients may not be candidates for finasteride therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; finasteride is extensively metabolized in the liver.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostate cancer: When compared to placebo, 5-alpha-reductase inhibitors (5-ARIs) have been associated with an increase in the incidence of high-grade prostate cancers; 5-ARIs are not approved in the US or Canada for the prevention of prostate cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Females/pregnancy: Active ingredient of crushed or broken tablets can be absorbed through the skin; unbroken tablets are coated which prevents contact with the active ingredient during normal handling. Pregnant females should avoid contact with crushed or broken tablets; finasteride may negatively impact fetal development.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Other urological diseases (including prostate cancer) should be ruled out before initiating (in BPH management). Not indicated for use in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: For BPH, a minimum of 6 months of treatment may be necessary to determine whether an individual will respond to finasteride; for male pattern hair loss, daily use for 3 months or longer may be required before benefit is observed (withdrawal of treatment leads to reversal of hair growth effect within 12 months).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; PSA monitoring: Reduces prostate specific antigen (PSA) concentration by ~50% within 6 months of treatment. To interpret serial PSAs, a new PSA baseline should be established &ge;6 months after treatment initiation and PSA monitored periodically thereafter. A confirmed PSA increase while on this medication, even if within normal limits, may be associated with an increased risk for prostate cancer and should be evaluated. Finasteride does not interfere with free PSA levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171339\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171270\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8447&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171272\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171286\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated in females of childbearing potential.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Abnormalities of external male genitalia were reported in animal reproduction studies. Pregnant females are advised to avoid contact with crushed or broken tablets.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adequate contraception is recommended if used off-label in the management hirsutism in females associated with PCOS (ACOG 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171287\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Use is contraindicated in women of childbearing potential.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">It is not known if finasteride is excreted in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171274\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">To interpret serial PSAs, establish a new PSA baseline &ge;6 months after treatment initiation and monitor PSA periodically thereafter. Objective and subjective signs of relief of benign prostatic hyperplasia, including improvement in urinary flow, reduction in symptoms of urgency, and relief of difficulty in micturition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171265\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Finasteride competitively inhibits type II 5-alpha reductase, resulting in inhibition of the conversion of testosterone to dihydrotestosterone and markedly suppresses serum dihydrotestosterone levels</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171282\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Dihydrotestosterone levels return to normal within 14 days of discontinuation of treatment; BPH: Prostate volume returns to baseline within ~3 months after discontinuation; Male pattern baldness: Reversal of increased hair count within 12 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>dss</sub>: 76 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~90% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (extensive) via CYP3A4; two active metabolites (&lt;20% activity of finasteride) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Mean: 5 mg: ~63%; 1 mg: 65% (not affected by food)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, serum: 5 to 6 hours (range: 3 to 16 hours); Elderly (&ge;70 years):  8 hours (range: 6 to 15 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (57%) and urine (39%; as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171285\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Finasteride Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $81.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $93.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Propecia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (30): $124.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Proscar Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $188.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171288\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alofecid (KR);</li>\n      <li>Alopec (BD);</li>\n      <li>Androfin (LV);</li>\n      <li>Aprodil (EC);</li>\n      <li>Atepros (PH);</li>\n      <li>Bearfina (KR);</li>\n      <li>Benstat (TH);</li>\n      <li>Binfin (SG);</li>\n      <li>Chibro-Proscar (FR);</li>\n      <li>Damocare (HK);</li>\n      <li>Damopecia (KR);</li>\n      <li>Daric (PY);</li>\n      <li>Fina-5 (PH);</li>\n      <li>Finapros (PH);</li>\n      <li>Finarid (PH);</li>\n      <li>Finas (BD, SG);</li>\n      <li>Finascar (JO);</li>\n      <li>Finaspro (TW);</li>\n      <li>Finaspros (CO);</li>\n      <li>Finast (LK, VN);</li>\n      <li>Finasta (AU);</li>\n      <li>Finastar (KR);</li>\n      <li>Finastid (HR);</li>\n      <li>Finated (KR);</li>\n      <li>Finatra (CN);</li>\n      <li>Fincar (HK, IN, KR, LK);</li>\n      <li>Finide (PH);</li>\n      <li>Finiscar (QA);</li>\n      <li>Finnacar (AU);</li>\n      <li>Finpro (ID, ZA);</li>\n      <li>Finstal-5 (PH);</li>\n      <li>Finster (LV);</li>\n      <li>Fintrid (IE);</li>\n      <li>Firide (TH);</li>\n      <li>Fistrin (CO);</li>\n      <li>For-BPH (PH);</li>\n      <li>Fynasid (TW);</li>\n      <li>GPO-Finax (TH);</li>\n      <li>Harifin (TH);</li>\n      <li>Jun Neng (CN);</li>\n      <li>Maxteride (HK);</li>\n      <li>Monastar (KR);</li>\n      <li>Penester (LV, UA);</li>\n      <li>Pro-Cure (IL);</li>\n      <li>Profal (IE);</li>\n      <li>Prohair (QA);</li>\n      <li>Pronax (PH);</li>\n      <li>Pronor (LK);</li>\n      <li>Propecia (AE, AR, AT, AU, BH, BR, BS, BZ, CN, CO, CR, CY, DO, EC, ES, GT, HK, HN, HR, IL, IS, JM, JP, KW, LB, LU, MT, MY, NI, NL, NZ, PA, PE, PH, QA, RO, SA, SE, SG, SV, TH, TT, TW);</li>\n      <li>Propeshia (MX);</li>\n      <li>Proscar (AE, AR, AT, AU, BB, BD, BE, BG, BH, BM, BO, BR, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, GB, GR, GT, GY, HK, HN, HR, HU, ID, IE, IT, JO, KR, KW, LB, LU, MT, MX, MY, NI, NO, NZ, PA, PE, PH, PK, PL, PR, PT, QA, RO, RU, SA, SE, SG, SK, SR, SV, TH, TR, TW, UA, VE, VN);</li>\n      <li>Proseride (TH);</li>\n      <li>Prosfin (BD);</li>\n      <li>Prostacare (LB, QA);</li>\n      <li>Prostan (UA);</li>\n      <li>Prostanus (PH);</li>\n      <li>Prostarinol (LV);</li>\n      <li>Prosterid (HU);</li>\n      <li>Prosteride (HK, PH, TH);</li>\n      <li>Prostide (ID);</li>\n      <li>Prostop (UY);</li>\n      <li>Proteside (JO);</li>\n      <li>Reprostom (ID);</li>\n      <li>Skarex (KR);</li>\n      <li>Stercia (SG);</li>\n      <li>Stercia-5 (TH);</li>\n      <li>Sterzar (TH);</li>\n      <li>Tensen (TW);</li>\n      <li>Urofin (UA);</li>\n      <li>Uromedin (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19888063\"></a>American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. <i>Obstet Gynecol</i>. 2009;114(4):936-49. doi: 10.1097/AOG.0b013e3181bd12cb.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/19888063/pubmed\" target=\"_blank\" id=\"19888063\">19888063</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15464773\"></a>Beigi A, Sobhi A, Zarrinkoub F. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. <i>Int J Gynaecol Obstet</i>. 2004;87(1):29-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/15464773/pubmed\" target=\"_blank\" id=\"15464773\">15464773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Irwig MS, &quot;Persistent Sexual Side Effects of Finasteride: Could They Be Permanent?&quot; <i>J Sex Med</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/22789024/pubmed\" target=\"_blank\" id=\"22789024\">22789024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(12):4565-4592. doi: 10.1210/jc.2013-2350.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/24151290/pubmed\" target=\"_blank\" id=\"24151290\">24151290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12749435\"></a>Lumachi F, Rondinone R. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. <i>Fertil Steril</i>. 2003;79(4):942-946.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/12749435/pubmed\" target=\"_blank\" id=\"12749435\">12749435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McConnell JD, Roehrborn CG, Bautista OM, et al, &ldquo;The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group,&rdquo; <i>N Engl J Med</i>, 2003, 349(25):2387-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/14681504/pubmed\" target=\"_blank\" id=\"14681504\">14681504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10634370\"></a>Moghetti P, Tosi F, Tosti A, et al, &ldquo;Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial,&rdquo; <i>J Clin Endocrinol Metab</i>, 2000, 85(1):89-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/10634370/pubmed\" target=\"_blank\" id=\"10634370\">10634370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pole M and Koren G, &ldquo;Finasteride. Does It Affect Spermatogenesis and Pregnancy,&rdquo; <i>Can Fam Physician</i>, 2001, 47:2469-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/11785276/pubmed\" target=\"_blank\" id=\"11785276\">11785276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Propecia (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Proscar (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15374729\"></a>Tartagni M, Schonauer MM, Cicinelli E, et al. Intermittent low-dose finasteride is as effective as daily administration for the treatment of hirsute women. <i>Fertil Steril</i>. 2004;82(3):752-755.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/15374729/pubmed\" target=\"_blank\" id=\"15374729\">15374729</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. <i>N Engl J Med</i>. 2003;349(3):215-224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/12824459/pubmed\" target=\"_blank\" id=\"12824459\">12824459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson IM Jr, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. <i>N Engl J Med</i>. 2013;369(7):603-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/finasteride-drug-information/abstract-text/23944298/pubmed\" target=\"_blank\" id=\"23944298\">23944298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8447 Version 190.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F47022773\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171302\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F171303\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F171346\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F171305\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F171306\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F171307\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F171308\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171276\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F171262\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F171280\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104520\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F171279\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725588\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171352\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171269\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171283\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171266\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F171339\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F171270\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171272\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F171286\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F171287\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F171274\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171265\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F171282\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F171285\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F171288\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8447|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=finasteride-patient-drug-information\" class=\"drug drug_patient\">Finasteride: Patient drug information</a></li></ul></div></div>","javascript":null}